What is the recommended treatment regimen for urticaria (hives)?

Treatment of Urticaria (Hives)

Start with a standard-dose second-generation H1-antihistamine (such as cetirizine, loratadine, fexofenadine, desloratadine, or levocetirizine) taken once daily, and if symptoms persist after 2-4 weeks, increase the dose up to 4-fold before considering other therapies. 1

First-Line Treatment: Second-Generation Antihistamines

• Begin with standard-dose second-generation H1-antihistamines as the initial therapy for all urticaria patients 1, 2
• Available options include cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and mizolastine, most taken once daily 2
• Patients should be offered a choice of at least two different antihistamines, as individual responses and tolerance vary significantly 2
• Avoid first-generation sedating antihistamines as monotherapy due to concerns about reduced concentration and performance 2

Second-Line Treatment: Updosing Antihistamines

• If inadequate control after 2-4 weeks (or earlier if symptoms are intolerable), increase the second-generation antihistamine dose up to 4-fold 1
• This updosing approach is effective in approximately 40-55% of patients with chronic spontaneous urticaria 3
• Continue the higher dose for at least 3 consecutive months of complete control before considering step-down 1
• When stepping down, reduce by no more than 1 tablet per month 1

Third-Line Treatment: Omalizumab

• For patients with inadequate control on high-dose antihistamines, add omalizumab 300 mg subcutaneously every 4 weeks 1
• Omalizumab achieves symptom control in 65-80% of antihistamine-resistant patients 3
• Allow up to 6 months for patients to respond to omalizumab 1
• If insufficient response occurs, consider updosing to 600 mg every 2 weeks (maximum recommended dose) 1
• Omalizumab has a superior risk-benefit profile compared to cyclosporine and is generally well-tolerated 1, 4

Fourth-Line Treatment: Cyclosporine

• For patients who fail omalizumab therapy (including higher doses), add cyclosporine up to 5 mg/kg body weight 1
• Cyclosporine achieves control in 70-80% of refractory cases 3
• Monitor blood pressure and renal function (blood urea nitrogen and creatinine) every 6 weeks during treatment 1
• Be aware of potential adverse effects including hypertension, renal impairment, hirsutism, and gum hypertrophy 1

Important Clinical Considerations

General Measures

• Minimize aggravating factors including overheating, stress, and alcohol 2
• Avoid aspirin and NSAIDs in patients with urticaria, as these can worsen symptoms 2
• Avoid ACE inhibitors in patients with angioedema without wheals, and use with caution if angioedema accompanies urticaria 2
• Cooling antipruritic lotions (calamine or 1% menthol in aqueous cream) can provide symptomatic relief 2

Treatment Algorithm Timing

• Assess response after 2-4 weeks at each step, or earlier if symptoms are intolerable 1
• The international guideline emphasizes an "as much as needed and as little as possible" approach 1
• Use the Urticaria Control Test (UCT) to assess disease control; a score ≤16 indicates inadequate control requiring treatment escalation 1

Common Pitfalls

• Do not use first-generation antihistamines as monotherapy due to sedation and impaired performance 2
• Do not add corticosteroids routinely for acute urticaria, as evidence shows no clear benefit when added to antihistamines 5
• Do not step down treatment too rapidly; maintain complete control for at least 3 consecutive months before reducing doses 1
• When control is lost during step-down, return to the last dose that provided complete control 1

Special Populations

• In pregnancy, avoid all antihistamines if possible, especially in the first trimester; chlorphenamine is often chosen when treatment is necessary due to its long safety record 2
• In renal impairment, halve the dose of cetirizine, levocetirizine, and hydroxyzine; avoid acrivastine in moderate impairment 2
• In hepatic impairment, mizolastine is contraindicated 2

Success Rates with Sequential Therapy

When using antihistamines, omalizumab, and cyclosporine in sequence, over 90% of patients can be successfully treated 3